University Hospital Waterford — Clinical Trial Site

38 Registered trials

17 Currently recruiting

Organisation

University Hospital Waterford

Location

Waterford, Ireland

Identifier

ORG-100040304

Address

Dunmore Road, X91 ER8E, Ireland

Departments

Cancer Research Department
Department of Dermatology
Department of Medical Oncology
Dermatology
Haem
Haematology
Haematology department
ICU
Medical Oncology
NA
Nephrology and General Internal Medicine
Neurology
Old School of Nursing
Oncology
Oncology Department
Oncology department
Stroke

Clinical trials at this site (38)

Search interface

Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 HER2-positive early breast cancer 5 2025-11-26
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting

2024-514135-17-00 Immunoglobulin A Nephropathy 5 2024-11-28
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4… Recruiting

2022-502825-17-00 Melanoma 4 2024-10-07
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting

2022-502548-12-00 marginal zone lymphoma 5 2023-09-28
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-11-28
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting

2024-516030-35-00 Multiple myeloma 5 2025-04-30
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and surv… Ended

2024-511306-23-00 Breast cancer, colon cancer, rectal cancer, stomach can 5 2024-07-01
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended

2024-512749-18-00 Newly diagnosed Multiple Myeloma 4 2022-03-03
A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended

2023-507698-16-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-10-14
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11